Please use this identifier to cite or link to this item:
Title: Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients
Authors: Wong, A.L.-A.
Yap, H.-L.
Yeo, W.-L. 
Soong, R.
Ng, S.-S.
Wang, L.-Z.
Cordero, M.T.
Yong, W.-P. 
Goh, B.-C.
Lee, S.-C. 
Keywords: Breast cancer
Genetic polymorphisms
Issue Date: Sep-2011
Citation: Wong, A.L.-A.,Yap, H.-L.,Yeo, W.-L.,Soong, R.,Ng, S.-S.,Wang, L.-Z.,Cordero, M.T.,Yong, W.-P.,Goh, B.-C.,Lee, S.-C. (2011-09). Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients. Cancer Genomics and Proteomics 8 (5) : 255-259. ScholarBank@NUS Repository.
Abstract: Background/Aim: Gemcitabine/carboplatin is efficacious in breast cancer but results in significant hematologic toxicities. We employed a multi-gene approach to identify variants to predict its toxicities. Patients and Methods: Twenty-six gemcitabine and platinum-based DNA repair pathway polymorphisms were correlated with gemcitabine pharmacokinetics, hematologic toxicities, response and survival in 41 Asian breast cancer patients receiving gemcitabine/ carboplatin. Results: The combined effects of solute carrier family (SLC)28A1+1528C>T and thymidylate synthetase (TYMS)+1494del6 significantly influenced hematologic toxicities: 89% of patients who possessed either SLC28A1+1528TT or TYMS+1494ins6/ins6 (n=9) developed grade 4 thrombocytopenia, versus 14% with neither genotype (n=29; p
Source Title: Cancer Genomics and Proteomics
ISSN: 11096535
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Page view(s)

checked on Jan 26, 2023

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.